U.S. markets open in 1 hour 33 minutes

Synaptogenix, Inc. (SNPX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.22-0.81 (-7.34%)
At close: 4:00PM EDT
10.10 -0.12 (-1.17%)
Pre-Market: 07:00AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close11.03
Open10.54
Bid0.00 x 1000
Ask12.00 x 2200
Day's Range9.38 - 11.70
52 Week Range2.60 - 14.40
Volume551,404
Avg. Volume214,744
Market Cap35.853M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Synaptogenix Announces $12.5 Million Private Placement
    PR Newswire

    Synaptogenix Announces $12.5 Million Private Placement

    Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it has executed securities purchase agreements to raise gross proceeds of approximately $12.5 million in a private placement financing of common stock and warrants ("Units"). The financing was led primarily by existing institutional shareholders.

  • Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update
    PR Newswire

    Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update

    Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD"). To date, the Company has now dosed 58 of its target 100 patients. Seventeen sites continue to be live.

  • Is Synaptogenix (NASDAQ:SNPX) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Synaptogenix (NASDAQ:SNPX) In A Good Position To Deliver On Growth Plans?

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...